Arch Biopartners Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2020 - 2016
Revenue	0.16	0.28	2.12	1.98	0.96	3.89	Upgrade
Revenue Growth (YoY)	-91.86%	-87.00%	6.97%	105.63%	-75.18%	5625.22%	Upgrade
Cost of Revenue	0.61	0.21	3.78	2.11	1.47	4.04	Upgrade
Gross Profit	-0.45	0.07	-1.66	-0.13	-0.5	-0.15	Upgrade
Selling, General & Admin	0.95	0.99	0.95	0.81	0.47	0.56	Upgrade
Operating Expenses	1.89	1.2	1.8	2.77	0.49	0.67	Upgrade
Operating Income	-2.34	-1.13	-3.46	-2.9	-1	-0.82	Upgrade
Interest Expense	-0.27	-0.26	-0.39	-0.36	-0.31	-0.27	Upgrade
Interest & Investment Income	-	-	0	0.02	-	-	Upgrade
Currency Exchange Gain (Loss)	0.01	-0.05	0.02	0.01	-0.02	-0	Upgrade
Other Non Operating Income (Expenses)	-0.09	-0.11	-0.1	-0.1	-0.08	-0.07	Upgrade
Pretax Income	-2.7	-1.55	-3.92	-3.33	-1.41	-1.17	Upgrade
Net Income	-2.7	-1.55	-3.92	-3.33	-1.41	-1.17	Upgrade
Net Income to Common	-2.7	-1.55	-3.92	-3.33	-1.41	-1.17	Upgrade
Shares Outstanding (Basic)	66	66	63	62	62	61	Upgrade
Shares Outstanding (Diluted)	66	66	63	62	62	61	Upgrade
Shares Change (YoY)	2.96%	3.51%	1.46%	0.49%	1.36%	2.34%	Upgrade
EPS (Basic)	-0.04	-0.02	-0.06	-0.05	-0.02	-0.02	Upgrade
EPS (Diluted)	-0.04	-0.02	-0.06	-0.05	-0.02	-0.02	Upgrade
Gross Margin	-284.90%	24.44%	-78.05%	-6.50%	-52.13%	-3.85%	Upgrade
Operating Margin	-1481.29%	-411.11%	-162.86%	-145.99%	-103.36%	-21.08%	Upgrade
Profit Margin	-1705.36%	-562.70%	-184.76%	-167.71%	-145.94%	-30.10%	Upgrade
EBIT	-2.34	-1.13	-3.46	-2.9	-1	-0.82	Upgrade
EBIT Margin	-	-	-162.86%	-145.99%	-103.36%	-21.08%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.